Alfuzosin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Alfuzosin
- Pharmacist Assessment Report
- Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Alfuzosin is an alpha-1 adrenergic receptor blocker originally used to treat benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Benign prostatic hyperplasia |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, alfuzosin is a selective alpha-1 adrenergic receptor antagonist. It relaxes smooth muscle in the prostate and bladder neck, which is why it works in BPH.
A plausible mechanistic link to the predicted indication has not been established. Ambras syndrome is a rare genetic form of hypertrichosis, associated with structural rearrangements on chromosome 8q that affect regulation of the TRPS1 gene. Blocking alpha-1 receptors has no known effect on this pathway. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
The other top-ranked predictions point the same way. They are mostly hair-related genetic conditions (hypertrichosis, trichomegaly, hair shaft abnormalities, hypotrichosis), plus a few developmental malformation syndromes. The same drug is predicted for opposing hair phenotypes (too much hair and too little hair). This suggests the model is picking up generic hair-phenotype associations. For hypertrichosis, the direction of effect is also unclear. Some vasoactive drugs, such as minoxidil, cause hypertrichosis rather than treat it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
All 20 registrations are valid single-ingredient licences. The data compiled for this report does not include approved-indication text. The table lists 5 of them.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 7778 | Alfuin 10mg Tablet | Strip of 10 tablets | Elio Biocare Lifesciences Pvt Ltd |
| 232426 | Urofuz 10mg Tablet | Strip of 10 tablets | Curis Lifecare |
| 4920 | Alfunex 10mg Tablet | Strip of 10 tablets | Nexkem Pharmaceuticals Pvt Ltd |
| 7592 | Alfuzin 10mg Tablet ER | Strip of 10 extended-release tablets | Astonea Labs Private Limited |
| 233503 | Velfu Tablet PR | Strip of 7 prolonged-release tablets | Intas Pharmaceuticals Ltd |
All products are oral tablets. Several are fixed-dose combinations with dutasteride (e.g., Sterdu L, Alfunol D, Emzosin D).
Safety Considerations
- Contraindications and risk conditions (from the knowledge graph, not label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, hypotensive disorder, long QT syndrome (including familial), torsades de pointes, liver failure, liver disease, gallbladder disease, and intraoperative floppy iris syndrome.
- Drug Interactions: 198 interactions were identified in total. The main ones are:
- Major: cisapride, clarithromycin, dolasetron. These are likely related to QT prolongation or CYP3A4 inhibition.
- Moderate: examples include famotidine, aprepitant, bupropion, levofloxacin, granisetron, and the SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin).
- Minor: cimetidine.
Package insert warnings were not available, so please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone (L5). There are no clinical trials or publications, and no plausible mechanism links alpha-1 blockade to Ambras-type hypertrichosis. The treatment direction is also uncertain, and the opposing hair phenotypes among the top predictions suggest a non-specific signal. None of the other nine ranked predictions is better supported.
To proceed, the following is needed:
- Mechanism of action data for alfuzosin, plus a biological rationale linking it to TRPS1 or hair follicle regulation
- Preclinical evidence (e.g., hair follicle models) showing a therapeutic rather than inducing effect
- Package insert warnings and contraindications from the India market, for a safety screening
- A review of whether the TxGNN model (deep learning) prediction reflects real biology or only similarities the model learned between related diseases
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.